Comparative Pharmacology
Head-to-head clinical analysis: FINGOLIMOD versus PIASKY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FINGOLIMOD versus PIASKY.
FINGOLIMOD vs PIASKY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sphingosine 1-phosphate receptor modulator; acts as a functional antagonist by downregulating S1P receptors on lymphocytes, preventing their egress from lymph nodes and reducing peripheral lymphocyte count.
PIASKY is a small molecule inhibitor of Bruton's tyrosine kinase (BTK), which irreversibly binds to the active site of BTK, blocking B-cell receptor signaling and inhibiting B-cell proliferation and survival.
0.5 mg orally once daily
10 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life is 6–9 days due to enteropathic recirculation and high Vd; clinical context: steady state reached in 1–2 months, duration of immunosuppression persists for weeks after discontinuation.
Clinical Note
moderateFingolimod + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Fingolimod."
Clinical Note
moderateFingolimod + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Fingolimod."
Clinical Note
moderateFingolimod + Doxycycline
"The metabolism of Doxycycline can be decreased when combined with Fingolimod."
Clinical Note
moderateFingolimod + Isavuconazonium
Terminal elimination half-life is approximately 6-8 hours in healthy adults; prolonged to 12-15 hours in moderate renal impairment (CrCl 30-60 mL/min) and up to 24 hours in severe impairment (CrCl <30 mL/min).
Primarily via biliary/fecal excretion (81% of dose recovered in feces as metabolites); renal excretion accounts for <2.5% of unchanged drug.
Primarily renal excretion as unchanged drug (approx. 80-90%) with minor biliary/fecal elimination (5-10%).
Category C
Category C
Sphingosine 1-Phosphate Receptor Modulator
Sphingosine 1-Phosphate Receptor Modulator
"The metabolism of Isavuconazonium can be decreased when combined with Fingolimod."